CCO Management Series
Fixed-Dose Combination NRTIs in the Treatment of HIV Infection
Efficacy and Safety of Fixed-Dose NRTIs
|
Module 1 of 3
|
Program Director:
John P. Phair, MD
|
|
 Topics covered include:
- Introduction
- Zidovudine/Lamivudine
- Abacavir/Lamivudine
- Tenofovir/Emtricitabine
- Zidovudine/Lamivudine/Abacavir
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the results of clinical studies that have compared the efficacy of various fixed-dose NRTIs. Describe the characteristics of available fixed-dose antiretroviral agents in the NRTI class. Identify significant and treatment-limiting side effects associated with the use of specific fixed-dose NRTIs.
|
NRTI Resistance and Fixed-Dose Antiretroviral Combinations
|
Module 2 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- NRTI Resistance
- Thymidine Analogue Mutations (TAMs)
- M184V
- L74V
Learning Objectives
Upon completion of this activity, participants should be able to:
Summarize data on resistance outcomes in patients who have experienced virologic failure on regimens containing NRTI fixed-dose combinations. Identify resistance mutations commonly associated with therapy with specific NRTIs. Describe how NRTI-associated resistance mutations affect susceptibility to other antiretrovirals.
|
Strategic Use and Sequencing of Fixed-Dose NRTIs
|
Module 3 of 3
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Advantages and Disadvantages of Zidovudine/Lamivudine
- Advantages and Disadvantages of Abacavir/Lamivudine
- Advantages and Disadvantages of Tenofovir/Emtricitabine
- Choosing a Dual NRTI Backbone in the Initial Regimen
Learning Objectives
Upon completion of this activity, participants should be able to:
Review considerations affecting the choice of the initial NRTI backbone using fixed-dose NRTIs, and options for subsequent NRTIs after first failure. Describe individual patient characteristics that may affect the decision whether to use fixed-dose NRTIs, including interactions, comorbidities, and special populations. Discuss principles that should be observed to ensure maximal benefit from fixed-dose NRTIs, including considerations regarding tolerability and impact on future options.
|
CCO Slidesets
Efficacy and Safety of Fixed-Dose NRTIs
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,059 KB
|
NRTI Resistance and Fixed-Dose Antiretroviral Combinations
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,705 KB
|
Strategic Use and Sequencing of Fixed-Dose NRTIs
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,498 KB
|
Interactive Case Challenges
Management of Adverse Effects in a Man Initiating Antiretroviral Therapy Using Fixed-Dose NRTIs
Program Director:
John P. Phair, MD
|
|
 William G. Powderly, MD, presents an interactive case study exploring strategies for the management of adverse effects in an HIV-infected patient initiating HAART with fixed-dose NRTIs. Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the short-term side effects of certain fixed-dose NRTI combinations. Describe the frequency and presentation of abacavir-related hypersensitivity reactions. Review data regarding zidovudine-related adverse events.
|
Management of Emergent Drug Resistance Following HAART Initiation With Fixed-Dose NRTIs
Program Director:
John P. Phair, MD
|
|
Trevor Hawkins, MD, presents an interactive case study exploring strategies for the management of emergent drug resistance in an HIV-infected patient initiating HAART with fixed-dose NRTIs. Learning Objectives
Upon completion of this activity, participants should be able to:
Review data regarding treatment of patients coinfected with HIV and hepatitis B virus (HBV). Describe interactions between viral mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Review data on hypersusceptibility to protease inhibitors (PIs).
|
Management of Long-Term Toxicities in a Man Initiating Antiretroviral Therapy Using Fixed-Dose NRTIs
Program Director:
John P. Phair, MD
|
|
Graeme Moyle, MD, MBBS, presents an interactive case study exploring strategies for the management of long-term toxicities with the use of fixed-dose NRTIs in HIV-infected patients. Learning Objectives
Upon completion of this activity, participants should be able to:
Describe strategies for managing HIV-infected patients with dyslipidemia and/or lipoatrophy. Discuss the association between NRTIs and lipoatrophy. Review data regarding renal abnormalities in patients receiving tenofovir.
|
Pocket Guide to Antiretroviral Resistance Mutations (PDF download)
Pocket Guide to Antiretroviral Resistance
One-page guide to resistance mutations associated with specific NRTIs, NNRTIs and PIs, and the effect of individual mutations on viral susceptibility to different drugs. Available as a PDF for effortless downloading and printing.
To sure you always have the latest version of this Pocket Guide, click here to receive an email bulletin whenever this resource is updated.
| Pocket Guide to Antiretroviral Resistance |
 Download |
| |
| Pocket Guide to Antiretroviral Resistance (black & white) |
Download |
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|